Marker Total Current Liabilities vs Net Debt Analysis

MRKR Stock

USD 4.07 0.13 3.30%

Marker Therapeutics financial indicator trend analysis is infinitely more than just investigating Marker Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Marker Therapeutics is a good investment. Please check the relationship between Marker Therapeutics Total Current Liabilities and its Net Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry.

To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.

Total Current Liabilities vs Net Debt

Total Current Liabilities vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Marker Therapeutics Total Current Liabilities account and Net Debt. At this time, the significance of the direction appears to have no relationship.

The correlation between Marker Therapeutics' Total Current Liabilities and Net Debt is 0.08. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Net Debt in the same time period over historical financial statements of Marker Therapeutics, assuming nothing else is changed. The correlation between historical values of Marker Therapeutics' Total Current Liabilities and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Marker Therapeutics are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Total Current Liabilities i.e., Marker Therapeutics' Total Current Liabilities and Net Debt go up and down completely randomly.

Correlation Coefficient

0.08

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Marker Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Marker Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Marker Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Marker Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry.

To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.As of 05/24/2024, Enterprise Value is likely to grow to about 27.1 M, while Selling General Administrative is likely to drop slightly above 5.6 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	3.2M	3.7M	4.2M	2.3M
Interest Income	5.7K	248.1K	447.2K	291.5K

Reconciled Depreciation Interest Income

Marker Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Non Currrent Assets Other	Property Plant Equipment
Total Assets		0.49	-0.06	0.07	0.93	0.48	-0.81	-0.72	0.71	0.92	0.65	0.92	0.19	-0.05	0.54	0.55	-0.06	0.75	0.75	0.36	0.5	0.95	-0.25	0.06	-0.18	0.34
Short Long Term Debt Total	0.49		-0.08	0.14	0.34	0.97	-0.06	-0.74	0.71	0.21	0.76	0.21	0.59	0.19	0.81	0.7	0.39	0.81	0.73	0.49	0.97	0.27	0.11	0.04	-0.72	0.82
Other Current Liab	-0.06	-0.08		0.94	-0.35	-0.05	0.06	0.04	0.06	-0.06	-0.01	-0.06	-0.07	0.23	-0.07	-0.03	-0.1	-0.05	-0.08	0.72	-0.04	-0.06	-0.13	0.24	0.13	-0.01
Total Current Liabilities	0.07	0.14	0.94		-0.27	0.1	0.08	-0.04	0.31	-0.02	0.23	-0.02	0.01	0.44	0.01	0.28	-0.08	0.17	0.0	0.89	0.11	-0.01	0.11	0.47	0.06	0.07
Total Stockholder Equity	0.93	0.34	-0.35	-0.27		0.34	-0.88	-0.66	0.51	0.94	0.44	0.94	0.12	-0.19	0.47	0.34	-0.07	0.58	0.71	0.0	0.36	0.95	-0.3	-0.1	-0.13	0.26
Property Plant And Equipment Net	0.48	0.97	-0.05	0.1	0.34		-0.1	-0.83	0.6	0.22	0.69	0.22	0.68	0.02	0.91	0.55	0.45	0.77	0.81	0.42	1.0	0.27	-0.08	-0.18	-0.78	0.91
Net Debt	-0.81	-0.06	0.06	0.08	-0.88	-0.1		0.54	-0.3	-0.97	-0.09	-0.97	0.11	0.12	-0.31	0.0	0.21	-0.26	-0.59	0.02	-0.12	-0.95	0.34	0.03	-0.1	-0.1
Retained Earnings	-0.72	-0.74	0.04	-0.04	-0.66	-0.83	0.54		-0.49	-0.59	-0.55	-0.59	-0.65	0.07	-0.94	-0.35	-0.17	-0.71	-1.0	-0.29	-0.83	-0.64	0.27	0.28	0.67	-0.81
Accounts Payable	0.71	0.71	0.06	0.31	0.51	0.6	-0.3	-0.49		0.49	0.81	0.49	0.07	0.21	0.44	0.85	0.15	0.81	0.49	0.64	0.64	0.52	0.12	0.4	-0.11	0.42
Cash	0.92	0.21	-0.06	-0.02	0.94	0.22	-0.97	-0.59	0.49		0.31	1.0	-0.04	-0.07	0.36	0.24	-0.19	0.46	0.64	0.14	0.24	1.0	-0.29	0.06	0.03	0.15
Non Current Assets Total	0.65	0.76	-0.01	0.23	0.44	0.69	-0.09	-0.55	0.81	0.31		0.31	0.47	0.02	0.52	0.93	0.18	0.94	0.53	0.65	0.71	0.37	-0.05	0.09	-0.45	0.46
Cash And Short Term Investments	0.92	0.21	-0.06	-0.02	0.94	0.22	-0.97	-0.59	0.49	1.0	0.31		-0.04	-0.07	0.36	0.24	-0.19	0.46	0.64	0.14	0.24	1.0	-0.29	0.06	0.03	0.15
Net Receivables	0.19	0.59	-0.07	0.01	0.12	0.68	0.11	-0.65	0.07	-0.04	0.47	-0.04		0.02	0.71	0.29	0.32	0.46	0.62	0.21	0.65	0.02	-0.06	-0.39	-0.87	0.69
Common Stock Total Equity	-0.05	0.19	0.23	0.44	-0.19	0.02	0.12	0.07	0.21	-0.07	0.02	-0.07	0.02		-0.03	0.28	-0.01	0.01	-0.09	0.35	0.02	-0.06	0.88	0.85	-0.02	0.02
Common Stock Shares Outstanding	0.54	0.81	-0.07	0.01	0.47	0.91	-0.31	-0.94	0.44	0.36	0.52	0.36	0.71	-0.03		0.31	0.44	0.69	0.93	0.26	0.91	0.41	-0.16	-0.3	-0.7	0.95
Non Current Liabilities Total	0.55	0.7	-0.03	0.28	0.34	0.55	0.0	-0.35	0.85	0.24	0.93	0.24	0.29	0.28	0.31		0.07	0.82	0.34	0.66	0.58	0.29	0.24	0.4	-0.32	0.28
Inventory	-0.06	0.39	-0.1	-0.08	-0.07	0.45	0.21	-0.17	0.15	-0.19	0.18	-0.19	0.32	-0.01	0.44	0.07		0.2	0.17	0.01	0.46	-0.16	0.1	-0.18	-0.25	0.6
Other Current Assets	0.75	0.81	-0.05	0.17	0.58	0.77	-0.26	-0.71	0.81	0.46	0.94	0.46	0.46	0.01	0.69	0.82	0.2		0.7	0.58	0.79	0.52	-0.1	0.05	-0.47	0.57
Other Stockholder Equity	0.75	0.73	-0.08	0.0	0.71	0.81	-0.59	-1.0	0.49	0.64	0.53	0.64	0.62	-0.09	0.93	0.34	0.17	0.7		0.25	0.81	0.68	-0.28	-0.28	-0.64	0.79
Total Liab	0.36	0.49	0.72	0.89	0.0	0.42	0.02	-0.29	0.64	0.14	0.65	0.14	0.21	0.35	0.26	0.66	0.01	0.58	0.25		0.44	0.17	0.06	0.42	-0.18	0.28
Property Plant And Equipment Gross	0.5	0.97	-0.04	0.11	0.36	1.0	-0.12	-0.83	0.64	0.24	0.71	0.24	0.65	0.02	0.91	0.58	0.46	0.79	0.81	0.44		0.29	-0.07	-0.16	-0.74	0.91
Total Current Assets	0.95	0.27	-0.06	-0.01	0.95	0.27	-0.95	-0.64	0.52	1.0	0.37	1.0	0.02	-0.06	0.41	0.29	-0.16	0.52	0.68	0.17	0.29		-0.29	0.05	-0.02	0.2
Short Term Debt	-0.25	0.11	-0.13	0.11	-0.3	-0.08	0.34	0.27	0.12	-0.29	-0.05	-0.29	-0.06	0.88	-0.16	0.24	0.1	-0.1	-0.28	0.06	-0.07	-0.29		0.78	0.08	-0.06
Common Stock	0.06	0.04	0.24	0.47	-0.1	-0.18	0.03	0.28	0.4	0.06	0.09	0.06	-0.39	0.85	-0.3	0.4	-0.18	0.05	-0.28	0.42	-0.16	0.05	0.78		0.36	-0.27
Non Currrent Assets Other	-0.18	-0.72	0.13	0.06	-0.13	-0.78	-0.1	0.67	-0.11	0.03	-0.45	0.03	-0.87	-0.02	-0.7	-0.32	-0.25	-0.47	-0.64	-0.18	-0.74	-0.02	0.08	0.36		-0.66
Property Plant Equipment	0.34	0.82	-0.01	0.07	0.26	0.91	-0.1	-0.81	0.42	0.15	0.46	0.15	0.69	0.02	0.95	0.28	0.6	0.57	0.79	0.28	0.91	0.2	-0.06	-0.27	-0.66

Click cells to compare fundamentals

Marker Therapeutics Account Relationship Matchups

Marker Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	46.4M	45.6M	68.1M	34.4M	17.1M	13.6M
Other Current Liab	30.7K	10.0	6.0M	3.1M	2.1M	2.4M
Total Current Liabilities	2.0M	6.4M	12.9M	7.8M	3.1M	4.6M
Total Stockholder Equity	44.1M	27.3M	44.0M	19.6M	14.1M	7.1M
Property Plant And Equipment Net	873.2K	21.2M	22.2M	17.8M	20.5M	21.5M
Net Debt	(43.4M)	(9.1M)	(30.5M)	(4.2M)	(15.1M)	(14.4M)
Retained Earnings	(327.5M)	(356.2M)	(398.1M)	(428.0M)	(436.3M)	(414.5M)
Accounts Payable	993K	2.9M	5.1M	1.6M	961.2K	1.3M
Cash	43.9M	21.4M	42.4M	11.8M	15.1M	9.6M
Cash And Short Term Investments	43.9M	21.4M	42.4M	11.8M	15.1M	9.6M
Net Receivables	56.2K	1.0M	237.0	2.4M	1.0M	1.1M
Common Stock Total Equity	10.6K	45.4K	45.7K	50.7K	58.3K	41.4K
Common Stock Shares Outstanding	4.6M	4.7M	7.7M	8.4M	8.8M	9.2M
Liabilities And Stockholders Equity	46.4M	45.6M	68.1M	34.4M	17.1M	13.6M
Non Current Liabilities Total	1.6M	280.2K	11.9M	11.2M	7.0M	0.0
Other Current Assets	1.5M	3.1M	3.6M	2.4M	988.1K	581.5K
Other Stockholder Equity	371.6M	383.5M	442.0M	447.6M	450.3M	472.8M
Total Liab	2.3M	18.3M	24.1M	14.8M	3.1M	6.0M
Property Plant And Equipment Gross	873.2K	21.2M	24.9M	17.8M	20.5M	21.5M
Total Current Assets	45.5M	24.4M	46.0M	16.6M	17.1M	10.3M
Short Term Debt	204.1K	388.8K	620.5K	577.2K	519.5K	481.1K
Common Stock	45.7K	50.7K	83.1K	8.4K	8.9K	8.4K
Non Currrent Assets Other	(472.0)	(21.2M)	2.2M	(17.8M)	(16.0M)	(15.2M)
Net Tangible Assets	59.3M	44.1M	27.3M	44.0M	50.6M	53.1M
Capital Surpluse	161.1M	365.4M	371.6M	383.5M	441.1M	230.6M
Net Invested Capital	44.1M	27.3M	44.0M	19.6M	14.1M	24.2M
Net Working Capital	43.5M	18.0M	33.1M	8.8M	14.1M	20.6M
Capital Stock	45.7K	50.7K	83.1K	8.4K	8.9K	8.4K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Marker Therapeutics is a strong investment it is important to analyze Marker Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Marker Therapeutics' future performance. For an informed investment choice regarding Marker Stock, refer to the following important reports:

How To Invest In Marker

Details

Is Marker Stock a good investment?

Details

What is Marker Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry.

To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Marker Stock analysis

When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.

	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios

Is Marker Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marker Therapeutics. If investors know Marker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marker Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.38)

Revenue Per Share

0.375

Quarterly Revenue Growth

0.008

Return On Assets

(0.38)

Return On Equity

(0.88)

The market value of Marker Therapeutics is measured differently than its book value, which is the value of Marker that is recorded on the company's balance sheet. Investors also form their own opinion of Marker Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Marker Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marker Therapeutics' market value can be influenced by many factors that don't directly affect Marker Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Marker Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marker Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marker Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Marker Total Current Liabilities vs Net Debt Analysis

Total Current Liabilities vs Net Debt

Total Current Liabilities vs Net Debt Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Net Debt

Marker Therapeutics fundamental ratios Correlations

Marker Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Marker Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Marker Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Net	+ 0.97	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.97	Short Long Term Debt Total

Other Stockholder Equity	- 1.0	Retained Earnings
Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Total Current Assets	- 0.95	Net Debt
Common Stock Shares Outstanding	- 0.94	Retained Earnings
Net Debt	- 0.88	Total Stockholder Equity